Oncogenic	O
mechanisms	O
of	O
Evi	O
-	O
1	O
protein	O
.	O

Although	O
Evi	O
-	O
1	O
is	O
thought	O
to	O
promote	O
growth	O
or	O
block	O
differentiation	O
in	O
some	O
cell	B-Cell
types	O
,	O
its	O
biological	O
functions	O
have	O
not	O
been	O
elucidated	O
.	O

To	O
explore	O
the	O
mechanisms	O
underlying	O
Evi	O
-	O
1	O
-	O
induced	O
oncogenesis	O
,	O
we	O
investigated	O
whether	O
Evi	O
-	O
1	O
affects	O
the	O
signaling	O
of	O
transforming	O
growth	O
factor	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
,	O
which	O
inhibits	O
proliferation	O
of	O
a	O
wide	O
range	O
of	O
cell	B-Cell
types	O
and	O
is	O
one	O
of	O
the	O
most	O
studied	O
growth	O
regulatory	O
factors	O
.	O

We	O
demonstrated	O
that	O
Evi	O
-	O
1	O
represses	O
TGF	O
-	O
beta	O
signaling	O
and	O
antagonizes	O
its	O
growth	O
-	O
inhibitory	O
effects	O
.	O

Two	O
separate	O
regions	O
of	O
Evi	O
-	O
1	O
are	O
responsible	O
for	O
this	O
repression	O
,	O
one	O
of	O
which	O
is	O
the	O
first	O
zinc	O
-	O
finger	O
domain	O
.	O

Through	O
this	O
domain	O
,	O
Evi	O
-	O
1	O
physically	O
interacts	O
with	O
Smad3	O
,	O
an	O
intracellular	B-Immaterial_anatomical_entity
mediator	O
of	O
TGF	O
-	O
beta	O
signaling	O
,	O
thereby	O
suppressing	O
the	O
transcriptional	O
activity	O
of	O
Smad3	O
.	O

These	O
results	O
define	O
a	O
novel	O
function	O
of	O
Evi	O
-	O
1	O
as	O
a	O
repressor	O
of	O
signaling	O
components	O
of	O
TGF	O
-	O
beta	O
.	O

We	O
also	O
demonstrated	O
that	O
Evi	O
-	O
1	O
represses	O
Smad	O
-	O
induced	O
transcriptional	O
activation	O
by	O
recruiting	O
CtBP	O
as	O
a	O
corepressor	O
.	O

Evi	O
-	O
1	O
associates	O
with	O
CtBP1	O
through	O
one	O
of	O
the	O
CtBP	O
-	O
binding	O
consensus	O
motifs	O
within	O
the	O
region	O
from	O
amino	O
acid	O
544	O
to	O
607	O
,	O
and	O
this	O
association	O
is	O
required	O
for	O
the	O
efficient	O
inhibition	O
of	O
TGF	O
-	O
beta	O
signaling	O
.	O

A	O
specific	O
histone	O
deacetylase	O
(	O
HDAc	O
)	O
inhibitor	O
,	O
trichostatin	O
A	O
(	O
TSA	O
)	O
,	O
alleviates	O
Evi	O
-	O
1	O
-	O
mediated	O
repression	O
of	O
TGF	O
-	O
beta	O
signaling	O
,	O
suggesting	O
that	O
HDAc	O
is	O
involved	O
in	O
transcriptional	O
repression	O
by	O
Evi	O
-	O
1	O
.	O

This	O
identifies	O
a	O
novel	O
function	O
of	O
Evi	O
-	O
1	O
as	O
a	O
member	O
of	O
corepressor	O
complexes	O
and	O
suggests	O
that	O
aberrant	O
recruitment	O
of	O
corepressors	O
is	O
one	O
of	O
the	O
mechanisms	O
involved	O
in	O
Evi	O
-	O
1	O
-	O
induced	O
leukemogenesis	O
.	O

These	O
results	O
indicate	O
that	O
specific	O
HDAc	O
inhibitors	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
Evi	O
-	O
1	O
-	O
induced	O
neoplastic	B-Cancer
tumors	I-Cancer
,	O
including	O
myeloid	B-Cancer
leukemias	I-Cancer
.	O

